Researches Index A to Z
Filter:
Is Ramipril Really Better Than Other Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction
Whether angiotensin-converting enzyme (ACE) inhibitors are interchangeable and equally efficacious after acute myocardial infarction (AMI) is controversial. We assessed whether ramipril was superior to other ACE inhibitors after AMI as suggested by a previously published study. We performed...
More
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
BACKGROUND Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly...
More
Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case–control study
Objectives: Controversy has been prompted based on drug interaction between proton pump inhibitors (PPIs) and aspirin/clopidogrel leading to weakened effects. However, whether such interaction was drug-specific or class effect remains controversial. This study predicted the impact of esomeprazole and...
More
Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study
Background: Globally the burden of chronic kidney disease (CKD) is rising, an important cause of death and loss of disability-adjusted life years. Activation of the renin-angiotensin-aldosterone system is involved in its pathogenesis. The aim of...
More
Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED
Hypertensive urgencies are a frequent cause for consultation at the emergency department (ED). There are multiple approaches to treating this presentation, and we endeavored to assess the safety and efficacy of an oral treatment with...
More
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study
Background: The Study of Micardis (telmisartan) in Overweight/Obese patients with Type 2 diabetes and Hypertension (SMOOTH) compared hydrochlorothiazide (HCTZ) plus telmisartan or valsartan fixed-dose combination therapies on early morning blood pressure (BP), using ambulatory BP...
More